Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the Company) (OTCQB Venture Market: INNV), an emerging over-the-counter (OTC) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve mens and womens health and vitality and respiratory diseases, announced today the submission of regulatory filings by its international distribution partner, Lavasta Pharma FZ-LLC, a company based in Dubai (Lavasta) for the commercialization of ProstaGorx in the United Arab Emirates and Kuwait. Lavasta also has rights to this product in the Kingdom of Saudi Arabia, Algeria, Egypt, Lebanon, Jordan, Morocco, Tunisia, Bahrain, Oman, Qatar and Turkey, among other countries and is currently expected to continue to file for approval in the rest of its territory during this year.
Innovus signed an exclusive distribution agreement with Lavasta for ProstaGorx in 2018 and already received an upfront payment for the license.
We continue to expand the potential sales territories of our products. ProstaGorx is our third product after Zestra and Zestra Glide expected to enter the Middle Eastern and North African countries, said Innovus Pharma CEO, Dr. Bassam Damaj. Lavasta has committed a first order of 10,000 units upon approval of the product, continued Dr. Damaj.
About ProstaGorx and Prostate Health
Prostate health issues affect millions of men and it is important to offer a natural, clinically tested, alternative product with a potentially approved claim for urologic symptoms of Benign Prostatic Hyperplasia (BPH). With multiple published clinical trials, ProstaGorx ingredients have been shown to:
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
- Work with the prescription drug finasteride to reduce actual prostate weight;
- Regulate dihydrotestosterone (DHT) production and hormones that influence prostate volume;
- Clinically reduce nocturia, and improve prostate symptoms in men with BPH or prostatitis;
- Clinically reduce overall rate of progression of prostate cancer in men; and
- Decrease serum prostate-specific antigen (PSA) levels, suppression of tumor growth and support urinary function.
An estimated 50% of men have histologic evidence of BPH by age 50 and 75% by age 80; in 40“50% of these men, BPH becomes clinically significant. BPH was one of the ten most common, and costly, diseases in men older than 50 years of age in a recent study in the United States.
ProstaGorx is approved by Health Canada as Natural Health Product for the symptoms of Benign Prostatic Hyperplasia (BPH) and has been commercially available in Canada since 2018.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (OTC) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve mens and womens health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (ANDA) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.zestra.com; www.zestraglide.com; www.fluticare.com; www.allervarx.com; www.apeaz.com; www.diabasens.com; and www.supplementhunt.com.
About Lavasta Pharma
Lavasta Pharma is a multi-specialty health care company focused on representing and commercializing innovative pharmaceuticals and over-the-counter consumer products that enable people to live life to its greatest potential. The companys services currently extend to cover the region of Africa, Middle East and Turkey.
Lavasta Pharma has a regional team that manages the strategic execution of commercial operations across the AFMET region with a sales force team on the ground of 150+ across the region.
Lavasta Pharma has 2 main affiliated companies: (a) Lavasta Pharma FZ-LLC in Dubai, UAE that serves as the main commercial hub for the AFMET Region and (b) Lavasta Pharma LLC- UK in London, UK that serves as the Marketing Authorization and Intellectual Property holding entity.
Innovus Pharma’s Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, receiving patent protection for any of its products, to successfully commercialize ProstaGorx and others in certain Middle Eastern, North African and West African countries and elsewhere and to achieve its other development, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent annual report on Form 10-K, and other filings made with the SEC. Copies of these reports are available from the SEC’s website or without charge from the Company.
Innovus Pharma Investor Relations